No profile data available.
Liquidia Corporation (LQDA) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Morrisville, United States, with about 216 full-time employees.
It reported revenue of $158.32 million for fiscal year 2025, up 1031.2% from fiscal year 2024, and net income of -$68.92 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $171.68 million, up 1842.7% from a year before. Its market capitalization was $2.45 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States.
Liquidia reported $158.32 million in revenue for fiscal year 2025, up 1031.2% from $14.00 million in fiscal year 2024. In Q2 2026 revenue was $171.68 million.
$2.45 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include United Therapeutics Corporation (UTHR), Mineralys Therapeutics, Inc. (MLYS), Palvella Therapeutics, Inc. (PVLA), Gossamer Bio, Inc. (GOSS).